Q & A: Pfizer – the Sandwich story, filling the gap
This article was originally published in Scrip
When downsizing strikes R&D in the middle of a debt crisis, its not good news to find out that the emptying site also needs flood defenses. But as Paul Carter, who led the task force that responded to Pfizer’s exodus from Sandwich tells Scrip’s Eleanor Malone, local and central government and business can work together to reduce the immediate impact, prevent a business disaster, and to manage the process.
You may also be interested in...
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.
The US election will intensify the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.